These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 7666524)

  • 1. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.
    Girard M; Meignier B; Barré-Sinoussi F; Kieny MP; Matthews T; Muchmore E; Nara PL; Wei Q; Rimsky L; Weinhold K
    J Virol; 1995 Oct; 69(10):6239-48. PubMed ID: 7666524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.
    Coëffier E; Girard M; Barré-Sinoussi F; Meignier B; Muchmore E; Fultz PN; LeClerc C
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1023-34. PubMed ID: 9718117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
    Girard M; van der Ryst E; Barré-Sinoussi F; Nara P; Tartaglia J; Paoletti E; Blondeau C; Jennings M; Verrier F; Meignier B; Fultz PN
    Virology; 1997 May; 232(1):98-104. PubMed ID: 9185593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.
    Girard M; Yue L; Barré-Sinoussi F; van der Ryst E; Meignier B; Muchmore E; Fultz PN
    J Virol; 1996 Nov; 70(11):8229-33. PubMed ID: 8892959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
    Berman PW; Murthy KK; Wrin T; Vennari JC; Cobb EK; Eastman DJ; Champe M; Nakamura GR; Davison D; Powell MF; Bussiere J; Francis DP; Matthews T; Gregory TJ; Obijeski JF
    J Infect Dis; 1996 Jan; 173(1):52-9. PubMed ID: 8537682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees.
    Belo M; Yagello M; Girard M; Greenlee R; Deslandres A; Barré-Sinoussi F; Gluckman JC
    AIDS; 1991 Feb; 5(2):169-76. PubMed ID: 2031689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.
    Zolla-Pazner S; Lubeck M; Xu S; Burda S; Natuk RJ; Sinangil F; Steimer K; Gallo RC; Eichberg JW; Matthews T; Robert-Guroff M
    J Virol; 1998 Feb; 72(2):1052-9. PubMed ID: 9444999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
    Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
    J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
    Robert-Guroff M; Kaur H; Patterson LJ; Leno M; Conley AJ; McKenna PM; Markham PD; Richardson E; Aldrich K; Arora K; Murty L; Carter L; Zolla-Pazner S; Sinangil F
    J Virol; 1998 Dec; 72(12):10275-80. PubMed ID: 9811775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
    Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.
    el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS
    AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization.
    Boyer JD; Wang B; Ugen KE; Agadjanyan M; Javadian A; Frost P; Dang K; Carrano RA; Ciccarelli R; Coney L; Williams WV; Weiner DB
    J Med Primatol; 1996 Jun; 25(3):242-50. PubMed ID: 8892046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
    Berman PW; Eastman DJ; Wilkes DM; Nakamura GR; Gregory TJ; Schwartz D; Gorse G; Belshe R; Clements ML; Byrn RA
    AIDS; 1994 May; 8(5):591-601. PubMed ID: 7520248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.